Evidence map›Paper›PMID 30798438›Full record

ArticlePituitary2019

Increased androgen secretion in patients with prolactinomas: the impact of altered HPA function.

Yosra Moria, Rouba Kortbawi, Nadine El-Asmar, Baha M Arafah

Abstract read
PubMed Publisher
In one paragraph

Article in Pituitary, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Hyperprolactinaemia.Journal of clinical medicine · 2019
    Review
  6. Characteristics of polycystic ovary syndrome throughout life.Therapeutic advances in reproductive health
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yosra MoriaDivision of Clinical and Molecular Endocrinology, UH Cleveland Medical Center and Case Western University, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
Rouba KortbawiDivision of Clinical and Molecular Endocrinology, UH Cleveland Medical Center and Case Western University, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
Nadine El-AsmarDivision of Clinical and Molecular Endocrinology, UH Cleveland Medical Center and Case Western University, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
Baha M ArafahDivision of Clinical and Molecular Endocrinology, UH Cleveland Medical Center and Case Western University, 11100 Euclid Avenue, Cleveland, OH, 44106, USA. baha.arafah@case.edu.
University Hospitals Cleveland Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesEarlier studies suggested that hyperprolactinemia was associated with elevated serum DHEA-S levels. The importance of DHEA-S measurements in the diagnosis of adrenal insufficiency prompted us to assess adrenal androgen levels in hyperprolactinemic subjects with normal or impaired function.

methodsProspective study including 122 medically treated and 26 surgically patients with prolactinomas. Serum PRL, DHEA and DHEA-S levels were measured before and repeatedly after cabergoline therapy and also in the perioperative period of surgically treated patients.

resultsSerum PRL levels decreased (P < 0.001) in all 101 medically treated patients with normal HPA function from 728.3 ± 1507 reaching 29.1 ± 39 and 14.9 ± 24.4 µg/L at 3 and 12 months, respectively. Concurrently serum DHEA-S levels decreased (P < 0.001) from 245.9 ± 196 to 216.2 ± 203.3 and to 169.7 ± 121.1 µg/dl at 3 and 12 months, respectively. These effects were reversed in 19 patients who discontinued treatment and were re-demonstrated after therapy resumption. Among the 22 surgically treated patients with normal HPA, peri-operative PRL levels decreased rapidly (P < 0.001) with a parallel decline in serum DHEA-S levels (P = 0.03). Strong correlations were noted between PRL and DHEA-S decrements observed with medical or surgical therapy. Medically (n = 21) and surgically (n = 4) patients with impaired HPA function had very low DHEA-S values that were unchanged despite marked reductions in PRL secretion.

conclusionHyperprolactinemia is associated with a reproducible and reversible increase in serum DHEA-S that was observed in medically- and surgically-treated patients with normal HPA function. Thus, a normal age- and gender-adjusted serum DHEA-S level continues to imply normal HPA function even among hyperprolactinemic subjects.

Indexed as

AdultDehydroepiandrosteroneDehydroepiandrosterone SulfateFemaleHumansHydrocortisoneHyperprolactinemiaHypothalamo-Hypophyseal SystemMaleMiddle AgedPituitary-Adrenal SystemProlactinProlactinomaProspective StudiesYoung AdultDehydroepiandrosteroneDehydroepiandrosterone SulfateHydrocortisoneProlactinDHEA-SHypothalamic–pituitary–adrenal axisProlactinoma

Identifiers

PMID30798438
OpenAlexW2915153716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.